Johnson & Johnson reported strong fourth quarter and full-year 2007 results, exceeding sales and earnings expectations. Management's optimistic guidance for 2008, along with strategic initiatives and a robust pipeline, instills confidence despite some headwinds from generic competition. The positive tone and commitment to shareholder value through share buybacks are likely to support the stock price in the short term.

[1]